Stock Track | Orthocell Shares Plummet 8.21% Intraday on Stagnant Quarterly Revenue

Stock Track

04/20

Orthocell Ltd's stock price plummeted 8.21% during intraday trading on Monday, following the company's quarterly financial update.

The biotech company reported revenue of AU$3.2 million for the March quarter, which was in line with the prior quarter's results and primarily driven by sales of its nerve repair product, Remplir. This lack of sequential growth appears to have disappointed investors despite positive forward-looking statements from the company.

Orthocell noted it expects a material uplift in US revenue in upcoming quarters after establishing a commercial distribution platform covering over 16 states, with regulatory approval for Remplir in the US and UK anticipated in the second half of 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1199733288"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199733288\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199733288?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-20 12:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199733288","market":"nz","top_or_hot":-1,"title":"Stock Track | Orthocell Shares Plummet 8.21% Intraday on Stagnant Quarterly Revenue","media":"Stock Track","content":"<p>Orthocell Ltd's stock price plummeted 8.21% during intraday trading on Monday, following the company's quarterly financial update.</p><p>The biotech company reported revenue of AU$3.2 million for the March quarter, which was in line with the prior quarter's results and primarily driven by sales of its nerve repair product, Remplir. This lack of sequential growth appears to have disappointed investors despite positive forward-looking statements from the company.</p><p>Orthocell noted it expects a material uplift in US revenue in upcoming quarters after establishing a commercial distribution platform covering over 16 states, with regulatory approval for Remplir in the US and UK anticipated in the second half of 2026.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Orthocell Shares Plummet 8.21% Intraday on Stagnant Quarterly Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Orthocell Shares Plummet 8.21% Intraday on Stagnant Quarterly Revenue\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-20 12:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Orthocell Ltd's stock price plummeted 8.21% during intraday trading on Monday, following the company's quarterly financial update.</p><p>The biotech company reported revenue of AU$3.2 million for the March quarter, which was in line with the prior quarter's results and primarily driven by sales of its nerve repair product, Remplir. This lack of sequential growth appears to have disappointed investors despite positive forward-looking statements from the company.</p><p>Orthocell noted it expects a material uplift in US revenue in upcoming quarters after establishing a commercial distribution platform covering over 16 states, with regulatory approval for Remplir in the US and UK anticipated in the second half of 2026.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCC.AU","symbol_name":"ORTHOCELL LTD","start_time":0,"source_url":"","article_id":"1199733288","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199733288","pubTimestamp":1776659309,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Orthocell Ltd's stock price plummeted 8.21% during intraday trading on Monday, following the company's quarterly financial update.The biotech company reported revenue of AU$3.2 million for the March...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCC.AU":"ORTHOCELL LTD"},"translate_title":"股票追踪|Orthocell股价盘中暴跌8.21%因季度营收停滞不前","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCC.AU":1},"content_text":"Orthocell Ltd's stock price plummeted 8.21% during intraday trading on Monday, following the company's quarterly financial update.The biotech company reported revenue of AU$3.2 million for the March quarter, which was in line with the prior quarter's results and primarily driven by sales of its nerve repair product, Remplir. This lack of sequential growth appears to have disappointed investors despite positive forward-looking statements from the company.Orthocell noted it expects a material uplift in US revenue in upcoming quarters after establishing a commercial distribution platform covering over 16 states, with regulatory approval for Remplir in the US and UK anticipated in the second half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}